Apyx Medical (NASDAQ:APYX) Issues Earnings Results

Apyx Medical (NASDAQ:APYX) announced its earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05, Zacks reports. Apyx Medical had a negative net margin of 37.11% and a negative return on equity of 158.22%. The company had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $12.00 million. Apyx Medical updated its FY 2025 guidance to EPS.

Apyx Medical Trading Up 15.5%

NASDAQ:APYX traded up $0.52 during trading hours on Friday, hitting $3.87. The company had a trading volume of 235,601 shares, compared to its average volume of 110,221. Apyx Medical has a 1 year low of $0.76 and a 1 year high of $3.99. The company has a market cap of $146.36 million, a P/E ratio of -8.60 and a beta of 1.60. The company has a 50-day moving average of $2.59 and a 200 day moving average of $2.09. The company has a current ratio of 4.72, a quick ratio of 3.95 and a debt-to-equity ratio of 4.61.

Institutional Investors Weigh In On Apyx Medical

A number of hedge funds have recently modified their holdings of APYX. Osaic Holdings Inc. acquired a new stake in Apyx Medical during the second quarter worth about $50,000. Vanguard Group Inc. grew its stake in shares of Apyx Medical by 3.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock valued at $3,272,000 after buying an additional 53,175 shares during the period. Finally, Nantahala Capital Management LLC increased its holdings in shares of Apyx Medical by 2.5% during the 2nd quarter. Nantahala Capital Management LLC now owns 3,338,048 shares of the company’s stock worth $7,511,000 after buying an additional 80,000 shares during the last quarter. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Apyx Medical in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

About Apyx Medical

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures.